Navigation Links
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
Date:5/14/2009

he demographic and blinded safety data from the ongoing Phase III study, the LUX-Lung 1 trial, will be presented at ASCO for the first time.(5)

The LUX-Lung 1 study addresses a critical need for treatment options for NSCLC patients after failure with a second-line or third-line reversible EGFR inhibitor (i.e., erlotinib or gefitinib). This study recently moved from Phase IIb into Phase III.(5)

"The LUX-Lung 1 study is important as it investigates BIBW 2992 in a group of patients for whom there are no other approved treatment options. These are patients who have already been through standard first-line or second-line chemotherapy and then received treatment with an EGFR TKI. The LUX-Lung 1 study will evaluate whether BIBW 2992 will extend the lives of these cancer patients,"(5) said Dr. Haehl.

First Presentation of Phase II Data on BIBF 1120 in Ovarian Cancer

Data from a Phase II study of BIBF 1120 in patients with ovarian cancer who responded to at least second-line chemotherapy will be presented at ASCO in Orlando. The study showed a potential delay in disease progression: With BIBF 1120 the median time to RECIST progression was 4.8, versus 2.8 for placebo.(11) BIBF 1120 is an oral compound that works by simultaneously inhibiting vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) -- all factors which are involved in the formation of blood vessels, a process known as angiogenesis.(12,13).

"There is a great need for more effective and well tolerated treatment options for women with ovarian cancer.(14) We have a growing body of evidence that anti-angiogenic agents may represent an important treatment approach for this disease,"(15,16,17) commented Prof. Jonathan A. Ledermann, MD, Professor of Medical Oncology & Director at the Cancer Research UK & UCL Cancer Trials
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)... Today, Rhodes Pharmaceuticals L.P. announced that Aptensio ... for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) will ... The announcement comes just one month ... Food and Drug Administration (FDA). ... capsule with an onset of effect of 1 ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6
... NATICK, Mass., Nov. 25, 2011  RegenoCELL Therapeutics, Inc. (OTCBB: ... is pleased to announce that its wholly owned subsidiary ... with several potential new distributors.  It is anticipated that ... and begin purchasing cell processing services in the near ...
... Biopharmaceutical Company Moleac has announced the launch in France and ... supplement engineered to stimulate neuroplasticity and recovery. NurAiD II is ... operated by Moleac and a growing number of pharmacies across ... to support the restoration of neurological functions: ...
Cached Medicine Technology:Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 2Regenocell in Negotiations With Potential New Distributors to Increase Patient Flow 3Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 2Moleac Announces the Launch of NurAiD II in France, a "Recovery Stimulator" Marketed as a Natural Food Supplement 3
(Date:5/22/2015)... PA (PRWEB) May 22, 2015 According to ... a hub for drug related death, totaling almost 2,500 confirmed ... as reported by state officials, totals 2,489 deaths stemming from ... work out, Pennsylvania loses seven people every day to fatal ... has been singled out as one of the most rife ...
(Date:5/22/2015)... VA (PRWEB) May 22, 2015 sweetFrog Enterprises, ... location in Jacksonville, Texas. Jacksonville is now the 16th sweetFrog ... yogurt chain was listed as #22 on the Inc. 500 ... “I have lived and worked in East Texas for 20 ... Brad Anderson, owner of the Jacksonville, and nearby Palestine, sweetFrog ...
(Date:5/22/2015)... Ticket Down is a reputable source for authentic ... Conference Finals Tickets . All seating for the 2015 ... ticket listing. , For the first time in some ... the Eastern Conference. One of the original franchises in the ... downs over the years, but the excitement level for this ...
(Date:5/22/2015)... Co founders Greenlee and James Chapko, DDS have launched a ... deliver fully integrated dental implant services to their patients. ... , The Center, whose name is ImplantWide, LLC ... dental implants. These 6 roadblocks can discourage any dentist ... of dental implants into his or her practice. ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 In efforts ... patrons, the section containing particular muscles stretches has been ... nearly 50% of stretches now complete, Chunk Fitness envisions ... planned to be filmed and released at a later ... be found here: http://www.chunkfitness.com/stretches . , About the ...
Breaking Medicine News(10 mins):Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3Health News:First of Its Kind Dental Implant Training and Surgicenter to Open in June 2
... Skeletal findings suggest men fighting over women took place even ... Men fighting over women? Nothing new there, based on the ... , Durham University-led researchers say that genetic evidence from 34 ... were the result of a tribal war over the need ...
... Md., June 13 The Blinded,American Veterans Foundation (BAVF), ... honor Maryland State Delegate Sheila Hixson., "We,re honored ... residents of Maryland,s District 20 and to the entire ... Spring, MD. "Her,tireless efforts as a legislator and community ...
... Cause of Work Disability in Europe, PARIS, ... treating patients with early, active rheumatoid arthritis (RA),with ... an,indirect cost savings of euro 4,845 (or approximately ... study) per patient per year compared to,MTX treatment ...
... of Mesothelioma Victim Will Address Effort to Find ... Lexi,Miletto, whose grandfather, Joseph Miletto died in 2005 ... the Gala Dinner on Friday,evening, June 27th, part ... Malignant Mesothelioma, which runs Thursday,June 26th through Saturday, ...
... LAUDERDALE, Fla., June 12 Synovics,Pharmaceuticals, Inc., (OTC ... that on June 6, 2008, it formalized,a strategic ... of a joint venture ("JV"). The JV between ... vehicle for Synovics to have access,to assets of ...
... reduction in time awake and a drop in anxiety levels ... moderate aerobic exercise can help reduce anxiety and improve the ... study. Heavy aerobic or moderate strength exercises don,t have the ... Sao Paulo divided 28 women and eight men with primary ...
Cached Medicine News:Health News:Pursuit of Females Dates Way, Way Back 2Health News:Blinded Vets Foundation to Honor Maryland State Delegate Sheila Hixson 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 2Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 3Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 4Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 5Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 6Health News:HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity 7Health News:Asbestos Tragedy and Hope 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 2Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 3Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 4Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 5Health News:Synovics Pharmaceuticals forms a Strategic Joint Venture with Maneesh Pharmaceuticals 6
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... Standard/Conventional Blade. Stainless steel. Lamp supplied ... tradition of high quality standard incandescent ... blades have been continually refined through ... over to minimize maintenance requirements. They ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
Medicine Products: